

Montserrat Garcia-Closas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7675876/publications.pdf>

Version: 2024-02-01

434
papers

41,777
citations

2975

93
h-index

3487

182
g-index

472
all docs

472
docs citations

472
times ranked

39486
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.	27.8	2,165
2	Assessing the Probability That a Positive Report is False: An Approach for Molecular Epidemiology Studies. Journal of the National Cancer Institute, 2004, 96, 434-442.	6.3	1,553
3	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
4	Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores. American Journal of Human Genetics, 2015, 97, 576-592.	6.2	1,098
5	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
6	Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLoS Medicine, 2010, 7, e1000279.	8.4	764
7	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
8	Type I and II Endometrial Cancers: Have They Different Risk Factors?. Journal of Clinical Oncology, 2013, 31, 2607-2618.	1.6	613
9	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	6.3	596
10	A common coding variant in CASP8 is associated with breast cancer risk. Nature Genetics, 2007, 39, 352-358.	21.4	591
11	Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nature Reviews Genetics, 2016, 17, 392-406.	16.3	559
12	NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet, The, 2005, 366, 649-659.	13.7	558
13	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. Nature, 2014, 514, 92-97.	27.8	548
14	Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 382.	7.4	546
15	Breast Cancer Risk Genes Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
16	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
17	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
18	A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nature Genetics, 2010, 42, 978-984.	21.4	493

#	ARTICLE	IF	CITATIONS
19	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
20	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). <i>Nature Genetics</i> , 2009, 41, 579-584.	21.4	487
21	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. <i>Nature Genetics</i> , 2009, 41, 585-590.	21.4	434
22	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	428
23	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. <i>Genetics in Medicine</i> , 2019, 21, 1708-1718.	2.4	415
24	Differences in Risk Factors for Breast Cancer Molecular Subtypes in a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 439-443.	2.5	394
25	Performance of Common Genetic Variants in Breast-Cancer Risk Models. <i>New England Journal of Medicine</i> , 2010, 362, 986-993.	27.0	376
26	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
27	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	21.4	367
28	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> , 2015, 47, 1294-1303.	21.4	357
29	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
30	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
31	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
32	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R92.	5.0	320
33	Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics. <i>PLoS Genetics</i> , 2008, 4, e1000054.	3.5	315
34	Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1558-68.	2.5	299
35	Genetic susceptibility to breast cancer. <i>Molecular Oncology</i> , 2010, 4, 174-191.	4.6	291
36	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289

#	ARTICLE	IF	CITATIONS
37	Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States. JAMA Oncology, 2016, 2, 1295.	7.1	285
38	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
39	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
40	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	21.4	256
41	Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446.	5.0	248
42	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	21.4	235
43	Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncology, The, 2008, 9, 359-366.	10.7	211
44	Pooled Analysis and Meta-analysis of Glutathione S-Transferase M1 and Bladder Cancer: A HuGE Review. American Journal of Epidemiology, 2002, 156, 95-109.	3.4	209
45	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	6.2	201
46	Polymorphisms in <i>GSTT1</i> , <i>GSTZ1</i> , and <i>CYP2E1</i> , Disinfection By-products, and Risk of Bladder Cancer in Spain. Environmental Health Perspectives, 2010, 118, 1545-1550.	6.0	194
47	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
48	Genetic insights into biological mechanisms governing human ovarian ageing. Nature, 2021, 596, 393-397.	27.8	183
49	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	12.8	178
50	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nature Reviews Clinical Oncology, 2020, 17, 687-705.	27.6	178
51	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	3.2	174
52	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
53	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics, 2012, 21, 5373-5384.	2.9	168
54	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. British Journal of Cancer, 2012, 107, 800-807.	6.4	163

#	ARTICLE	IF	CITATIONS
55	<i>CHKE2</i> *1100delC Heterozygosity in Women With Breast Cancer Associated With Early Death, Breast Cancer-Specific Death, and Increased Risk of a Second Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 4308-4316.	1.6	162
56	Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors. <i>Nature Genetics</i> , 2016, 48, 1330-1338.	21.4	161
57	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
58	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. <i>Human Molecular Genetics</i> , 2011, 20, 3289-3303.	2.9	152
59	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	6.3	152
60	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for <i>CHKE2</i> *1100delC Carriers. <i>Journal of Clinical Oncology</i> , 2016, 34, 2750-2760.	1.6	152
61	Smoking and Bladder Cancer in Spain: Effects of Tobacco Type, Timing, Environmental Tobacco Smoke, and Gender. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1348-1354.	2.5	148
62	Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. <i>Human Genetics</i> , 2006, 119, 376-388.	3.8	144
63	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
64	Intragenic ATM Methylation in Peripheral Blood DNA as a Biomarker of Breast Cancer Risk. <i>Cancer Research</i> , 2012, 72, 2304-2313.	0.9	142
65	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	21.4	141
66	Genetic Variation in the Nucleotide Excision Repair Pathway and Bladder Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 536-542.	2.5	139
67	Genome-wide association study identifies multiple loci associated with bladder cancer risk. <i>Human Molecular Genetics</i> , 2014, 23, 1387-1398.	2.9	137
68	Evidence of Gene-Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. <i>PLoS Genetics</i> , 2013, 9, e1003284.	3.5	136
69	Mosaic loss of chromosome Y is associated with common variation near TCL1A. <i>Nature Genetics</i> , 2016, 48, 563-568.	21.4	134
70	Genetic Polymorphisms in Base-Excision Repair Pathway Genes and Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 353-358.	2.5	132
71	Established breast cancer risk factors by clinically important tumour characteristics. <i>British Journal of Cancer</i> , 2006, 95, 123-129.	6.4	127
72	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125

#	ARTICLE	IF	CITATIONS
73	A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. <i>Carcinogenesis</i> , 1997, 18, 2127-2132.	2.8	122
74	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
75	Large-Scale Evaluation of Candidate Genes Identifies Associations between VEGF Polymorphisms and Bladder Cancer Risk. <i>PLoS Genetics</i> , 2007, 3, e29.	3.5	119
76	Intrauterine environments and breast cancer risk: meta-analysis and systematic review. <i>Breast Cancer Research</i> , 2008, 10, R8.	5.0	118
77	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. <i>PLoS Medicine</i> , 2016, 13, e1002105.	8.4	118
78	Food, nutrient and heterocyclic amine intake and the risk of bladder cancer. <i>European Journal of Cancer</i> , 2007, 43, 1731-1740.	2.8	117
79	Genetic Susceptibility Loci for Breast Cancer by Estrogen Receptor Status. <i>Clinical Cancer Research</i> , 2008, 14, 8000-8009.	7.0	115
80	Genetic variation in the base excision repair pathway and bladder cancer risk. <i>Human Genetics</i> , 2007, 121, 233-242.	3.8	113
81	Pathway Analysis of Breast Cancer Genome-Wide Association Study Highlights Three Pathways and One Canonical Signaling Cascade. <i>Cancer Research</i> , 2010, 70, 4453-4459.	0.9	112
82	Mosaic Uniparental Disomies and Aneuploidies as Large Structural Variants of the Human Genome. <i>American Journal of Human Genetics</i> , 2010, 87, 129-138.	6.2	111
83	DNA Banking for Epidemiologic Studies: A Review of Current Practices. <i>Epidemiology</i> , 2002, 13, 246-254.	2.7	110
84	GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. <i>Carcinogenesis</i> , 2011, 32, 182-189.	2.8	110
85	Genetic polymorphisms in the one-carbon metabolism pathway and breast cancer risk: A population-based case-control study and meta-analyses. <i>International Journal of Cancer</i> , 2007, 120, 2696-2703.	5.1	107
86	Polymorphisms in DNA Repair Genes, Smoking, and Bladder Cancer Risk: Findings from the International Consortium of Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 6857-6864.	0.9	107
87	Common Genetic Polymorphisms Modify the Effect of Smoking on Absolute Risk of Bladder Cancer. <i>Cancer Research</i> , 2013, 73, 2211-2220.	0.9	107
88	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003173.	3.5	105
89	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014, 5, 4999.	12.8	105
90	Combined Associations of Genetic and Environmental Risk Factors: Implications for Prevention of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju305-dju305.	6.3	101

#	ARTICLE	IF	CITATIONS
91	Characterization of Large Structural Genetic Mosaicism in Human Autosomes. American Journal of Human Genetics, 2015, 96, 487-497.	6.2	101
92	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Human Molecular Genetics, 2011, 20, 4282-4289.	2.9	100
93	19p13.1 Is a Triple-Negative-Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.9	100
94	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Research, 2016, 76, 5103-5114.	0.9	100
95	Risk of Estrogen Receptor-Positive and -Negative Breast Cancer and Single-Nucleotide Polymorphism 2q35-rs13387042. Journal of the National Cancer Institute, 2009, 101, 1012-1018.	6.3	99
96	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nature Genetics, 2012, 44, 1182-1184.	21.4	99
97	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute, 2015, 107, djv219.	6.3	99
98	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. American Journal of Human Genetics, 2013, 93, 1046-1060.	6.2	98
99	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
100	Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. PLoS Genetics, 2016, 12, e1006493.	3.5	98
101	Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clinical Epigenetics, 2015, 7, 67.	4.1	95
102	Relationship between serum hormone concentrations, reproductive history, alcohol consumption and genetic polymorphisms in pre-menopausal women. International Journal of Cancer, 2002, 102, 172-178.	5.1	94
103	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 2016, 53, 298-309.	3.2	94
104	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
105	Racial and Ethnic Disparities in Excess Deaths During the COVID-19 Pandemic, March to December 2020. Annals of Internal Medicine, 2021, 174, 1693-1699.	3.9	93
106	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
107	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
108	Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 2008, 29, 1955-1962.	2.8	88

#	ARTICLE	IF	CITATIONS
109	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. <i>International Journal of Epidemiology</i> , 2018, 47, 526-536.	1.9	88
110	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
111	Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. <i>Carcinogenesis</i> , 2007, 28, 1788-1793.	2.8	87
112	A case-control study of cytochrome P450 1A1, glutathione S-transferase M1, cigarette smoking and lung cancer susceptibility (Massachusetts, United States). <i>Cancer Causes and Control</i> , 1997, 8, 544-553.	1.8	86
113	Female chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome. <i>Nature Communications</i> , 2016, 7, 11843.	12.8	86
114	Risk of Bladder Cancer Associated with Family History of Cancer: Do Low-Penetrance Polymorphisms Account for the Increase in Risk?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1595-1600.	2.5	85
115	Association of ESR1 gene tagging SNPs with breast cancer risk. <i>Human Molecular Genetics</i> , 2009, 18, 1131-1139.	2.9	84
116	Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study. <i>Breast Cancer Research</i> , 2010, 12, R110.	5.0	82
117	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2019, 48, 795-806.	1.9	81
118	Genomic and evolutionary classification of lung cancer in never smokers. <i>Nature Genetics</i> , 2021, 53, 1348-1359.	21.4	81
119	Glutathione S-Transferase Mu and Theta Polymorphisms and Breast Cancer Susceptibility. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1960-1964.	6.3	80
120	The role of genetic breast cancer susceptibility variants as prognostic factors. <i>Human Molecular Genetics</i> , 2012, 21, 3926-3939.	2.9	80
121	Common genetic variants in the <i>PSCA</i> gene influence gene expression and bladder cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4974-4979.	7.1	79
122	Differential Misclassification and the Assessment of Gene-Environment Interactions in Case-Control Studies. <i>American Journal of Epidemiology</i> , 1998, 147, 426-433.	3.4	78
123	Tagging Single Nucleotide Polymorphisms in Cell Cycle Control Genes and Susceptibility to Invasive Epithelial Ovarian Cancer. <i>Cancer Research</i> , 2007, 67, 3027-3035.	0.9	78
124	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016, 7, 12675.	12.8	78
125	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv315.	6.3	77
126	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.2	76

#	ARTICLE	IF	CITATIONS
127	<i>ESR1/SYNE1</i> Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 245-250.	2.5	75
128	<i>LIN28B</i> Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. Cancer Research, 2011, 71, 3896-3903.	0.9	75
129	Genetic and Non-genetic Predictors of LINE-1 Methylation in Leukocyte DNA. Environmental Health Perspectives, 2013, 121, 650-656.	6.0	75
130	<i>BRCA2</i> Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
131	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nature Communications, 2020, 11, 3353.	12.8	75
132	Cigarette Smoking and Cancer Risk: Modeling Total Exposure and Intensity. American Journal of Epidemiology, 2007, 166, 479-489.	3.4	73
133	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	5.1	73
134	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 4693-4706.	2.9	71
135	Replication and Functional Genomic Analyses of the Breast Cancer Susceptibility Locus at 6q25.1 Generalize Its Importance in Women of Chinese, Japanese, and European Ancestry. Cancer Research, 2011, 71, 1344-1355.	0.9	71
136	Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Human Molecular Genetics, 2012, 21, 1918-1930.	2.9	71
137	Genetic variation in five genes important in telomere biology and risk for breast cancer. British Journal of Cancer, 2007, 97, 832-836.	6.4	70
138	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
139	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	2.4	67
140	Pooled Analysis of Nine Cohorts Reveals Breast Cancer Risk Factors by Tumor Molecular Subtype. Cancer Research, 2018, 78, 6011-6021.	0.9	67
141	Comparison of yield and genotyping performance of multiple displacement amplification and OmniPlex, a whole genome amplified DNA generated from multiple DNA sources. Human Mutation, 2005, 26, 262-270.	2.5	63
142	Total Fluid and Water Consumption and the Joint Effect of Exposure to Disinfection By-Products on Risk of Bladder Cancer. Environmental Health Perspectives, 2007, 115, 1569-1572.	6.0	63
143	Single Nucleotide Polymorphisms in the <i>TP53</i> Region and Susceptibility to Invasive Epithelial Ovarian Cancer. Cancer Research, 2009, 69, 2349-2357.	0.9	63
144	Genetic Susceptibility to Distinct Bladder Cancer Subphenotypes. European Urology, 2010, 57, 283-292.	1.9	63

#	ARTICLE	IF	CITATIONS
145	Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF- α -LTA) and breast cancer risk. Human Genetics, 2007, 121, 483-490.	3.8	62
146	Discovery and validation of methylation markers for endometrial cancer. International Journal of Cancer, 2014, 135, 1860-1868.	5.1	62
147	Two Estrogen-Related Variants in <i>CYP19A1</i> and Endometrial Cancer Risk: A Pooled Analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 242-247.	2.5	61
148	Comparative Validation of Breast Cancer Risk Prediction Models and Projections for Future Risk Stratification. Journal of the National Cancer Institute, 2020, 112, 278-285.	6.3	61
149	iCARE: An R package to build, validate and apply absolute risk models. PLoS ONE, 2020, 15, e0228198.	2.5	61
150	Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer. International Journal of Cancer, 2007, 120, 2452-2458.	5.1	60
151	DNA Hypermethylation of <i>ESR1</i> and <i>PGR</i> in Breast Cancer: Pathologic and Epidemiologic Associations. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 3036-3043.	2.5	60
152	Temporal Stability and Determinants of White Blood Cell DNA Methylation in the Breakthrough Generations Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 221-229.	2.5	60
153	A framework for transcriptome-wide association studies in breast cancer in diverse study populations. Genome Biology, 2020, 21, 42.	8.8	60
154	A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenetics and Genomics, 2011, 21, 231-236.	1.5	60
155	Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes and Control, 2010, 21, 77-82.	1.8	59
156	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
157	Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. Journal of Medical Genetics, 2012, 49, 601-608.	3.2	58
158	Relationship between crown-like structures and sex-steroid hormones in breast adipose tissue and serum among postmenopausal breast cancer patients. Breast Cancer Research, 2017, 19, 8.	5.0	58
159	The Obesity-Associated Polymorphisms FTO rs9939609 and MC4R rs17782313 and Endometrial Cancer Risk in Non-Hispanic White Women. PLoS ONE, 2011, 6, e16756.	2.5	58
160	Five Polymorphisms and Breast Cancer Risk: Results from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1610-1616.	2.5	57
161	The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer. Human Mutation, 2006, 27, 538-544.	2.5	56
162	Adulthood Lifetime Physical Activity and Breast Cancer. Epidemiology, 2008, 19, 226-236.	2.7	56

#	ARTICLE	IF	CITATIONS
163	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. Human Molecular Genetics, 2014, 23, 2490-2497.	2.9	56
164	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine, 2015, 2, 681-689.	6.1	56
165	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	6.3	56
166	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Research, 2016, 18, 104.	5.0	56
167	Common genetic variants in the 9p21 region and their associations with multiple tumours. British Journal of Cancer, 2013, 108, 1378-1386.	6.4	55
168	Combined Utility of 25 Disease and Risk Factor Polygenic Risk Scores for Stratifying Risk of All-Cause Mortality. American Journal of Human Genetics, 2020, 107, 418-431.	6.2	55
169	Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 992-999.	2.5	54
170	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	2.5	54
171	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
172	Genetic variation in TP53 and risk of breast cancer in a population-based caseâ€“control study. Carcinogenesis, 2007, 28, 1680-1686.	2.8	53
173	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	2.9	53
174	Lessons Learned From Past Gene-Environment Interaction Successes. American Journal of Epidemiology, 2017, 186, 778-786.	3.4	53
175	Epidemiologic determinants of vaginal pH. American Journal of Obstetrics and Gynecology, 1999, 180, 1060-1066.	1.3	52
176	Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry. Breast Cancer Research, 2016, 18, 124.	5.0	52
177	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
178	Detection of Somatic Mutations by High-Resolution DNA Melting (HRM) Analysis in Multiple Cancers. PLoS ONE, 2011, 6, e14522.	2.5	52
179	Expression of TGF-Î² signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics. Breast Cancer Research and Treatment, 2010, 121, 727-735.	2.5	51
180	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Medicine, 2015, 13, 156.	5.5	51

#	ARTICLE	IF	CITATIONS
181	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. <i>International Journal of Cancer</i> , 2016, 139, 1303-1317.	5.1	51
182	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, 6574.	3.3	51
183	Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. <i>Modern Pathology</i> , 2019, 32, 1244-1256.	5.5	51
184	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). <i>PLoS ONE</i> , 2012, 7, e42380.	2.5	51
185	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. <i>JAMA Oncology</i> , 2022, 8, e216744.	7.1	51
186	Hormonal Markers in Breast Cancer: Coexpression, Relationship with Pathologic Characteristics, and Risk Factor Associations in a Population-Based Study. <i>Cancer Research</i> , 2007, 67, 10608-10617.	0.9	50
187	Genome-wide interaction study of smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2014, 35, 1737-1744.	2.8	50
188	Common genetic variation in <i>TP53</i> and its flanking genes, <i>WDR79</i> and <i>ATP1B2</i> , and susceptibility to breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 2532-2538.	5.1	49
189	Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. <i>British Journal of Cancer</i> , 2008, 98, 282-288.	6.4	49
190	TGF- β 2 Signaling Pathway and Breast Cancer Susceptibility. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1112-1119.	2.5	49
191	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	2.5	49
192	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. <i>Breast Cancer Research</i> , 2021, 23, 22.	5.0	49
193	Hair dye use is not associated with risk for bladder cancer: Evidence from a case-control study in Spain. <i>European Journal of Cancer</i> , 2006, 42, 1448-1454.	2.8	48
194	Estimating age-specific breast cancer risks: a descriptive tool to identify age interactions. <i>Cancer Causes and Control</i> , 2007, 18, 439-447.	1.8	48
195	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility "Hot-Spot". <i>PLoS Genetics</i> , 2010, 6, e1001016.	3.5	48
196	Association Between a Germline OCA2 Polymorphism at Chromosome 15q13.1 and Estrogen Receptor-Negative Breast Cancer Survival. <i>Journal of the National Cancer Institute</i> , 2010, 102, 650-662.	6.3	48
197	Risk of Ovarian Cancer and the NF- κ B Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . <i>Cancer Research</i> , 2014, 74, 852-861.	0.9	48
198	A role for XRCC2 gene polymorphisms in breast cancer risk and survival. <i>Journal of Medical Genetics</i> , 2011, 48, 477-484.	3.2	47

#	ARTICLE	IF	CITATIONS
199	Analysis of Serum Metabolic Profiles in Women with Endometrial Cancer and Controls in a Population-Based Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3216-3223.	3.6	46
200	Identification of novel breast cancer susceptibility loci in meta-analyses conducted among Asian and European descendants. <i>Nature Communications</i> , 2020, 11, 1217.	12.8	46
201	Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-muscle-Invasive Bladder Cancer. <i>Cancer Prevention Research</i> , 2010, 3, 1235-1245.	1.5	45
202	Ovarian Cancer Risk Associated with Inherited Inflammation-Related Variants. <i>Cancer Research</i> , 2012, 72, 1064-1069.	0.9	45
203	Body mass index and breast cancer survival: a Mendelian randomization analysis. <i>International Journal of Epidemiology</i> , 2017, 46, 1814-1822.	1.9	45
204	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	6.3	45
205	Loss of antigenicity in stored sections of breast cancer tissue microarrays. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 667-72.	2.5	45
206	Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population-based analysis. <i>International Journal of Cancer</i> , 2007, 121, 1079-1085.	5.1	44
207	TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis. <i>International Journal of Cancer</i> , 2009, 124, 608-613.	5.1	44
208	Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. <i>International Journal of Cancer</i> , 2006, 119, 1961-1969.	5.1	43
209	Reproductive risk factors for endometrial cancer among Polish women. <i>British Journal of Cancer</i> , 2007, 96, 1450-1456.	6.4	43
210	Genetic predisposition to ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2016, 18, 22.	5.0	43
211	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. <i>Breast Cancer Research</i> , 2017, 19, 119.	5.0	43
212	Immune gene expression profiling reveals heterogeneity in luminal breast tumors. <i>Breast Cancer Research</i> , 2019, 21, 147.	5.0	43
213	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. <i>International Journal of Epidemiology</i> , 2022, 50, 1897-1911.	1.9	43
214	Use of Analgesics and Nonsteroidal Anti-inflammatory Drugs, Genetic Predisposition, and Bladder Cancer Risk in Spain. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1696-1702.	2.5	42
215	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. <i>Human Molecular Genetics</i> , 2009, 18, 2297-2304.	2.9	42
216	Common genetic variation in the sex hormone metabolic pathway and endometrial cancer risk: pathway-based evaluation of candidate genes. <i>Carcinogenesis</i> , 2010, 31, 827-833.	2.8	42

#	ARTICLE	IF	CITATIONS
217	Genome-wide association study of endometrial cancer in E2C2. <i>Human Genetics</i> , 2014, 133, 211-224.	3.8	42
218	Infertility and incident endometrial cancer risk: a pooled analysis from the epidemiology of endometrial cancer consortium (E2C2). <i>British Journal of Cancer</i> , 2015, 112, 925-933.	6.4	41
219	Lifetime Number of Ovulatory Cycles and Risks of Ovarian and Endometrial Cancer Among Postmenopausal Women. <i>American Journal of Epidemiology</i> , 2016, 183, 800-814.	3.4	41
220	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1168-1176.	6.3	41
221	Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Breast Cancer. <i>Cancer Research</i> , 2015, 75, 2844-2850.	0.9	40
222	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015, 24, 2966-2984.	2.9	40
223	Impact of Population Growth and Aging on Estimates of Excess U.S. Deaths During the COVID-19 Pandemic, March to August 2020. <i>Annals of Internal Medicine</i> , 2021, 174, 437-443.	3.9	40
224	Asbestos-related diseases in construction carpenters. <i>American Journal of Industrial Medicine</i> , 1995, 27, 115-125.	2.1	39
225	A cross-sectional study of dental caries, intake of confectionery and foods rich in starch and sugars, and salivary counts of <i>Streptococcus mutans</i> in children in Spain. <i>American Journal of Clinical Nutrition</i> , 1997, 66, 1257-1263.	4.7	39
226	Analysis of terminal duct lobular unit involution in luminal A and basal breast cancers. <i>Breast Cancer Research</i> , 2012, 14, R64.	5.0	39
227	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.5	39
228	Patient survival and tumor characteristics associated with CHEK2:p.I157T â€œ findings from the Breast Cancer Association Consortium. <i>Breast Cancer Research</i> , 2016, 18, 98.	5.0	39
229	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020, 107, 837-848.	6.2	39
230	Occupational exposure to organic solvents and breast cancer in women. <i>Occupational and Environmental Medicine</i> , 2010, 67, 722-729.	2.8	38
231	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015, 24, 285-298.	2.9	38
232	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. <i>Human Molecular Genetics</i> , 2016, 25, 1203-1214.	2.9	38
233	Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study. <i>BMC Cancer</i> , 2007, 7, 60.	2.6	37
234	Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. <i>Breast Cancer Research and Treatment</i> , 2009, 113, 189-196.	2.5	37

#	ARTICLE	IF	CITATIONS
235	Urinary pH, cigarette smoking and bladder cancer risk. <i>Carcinogenesis</i> , 2011, 32, 843-847.	2.8	37
236	Likelihood Ratio Test for Detecting Gene (G)-Environment (E) Interactions Under an Additive Risk Model Exploiting G-E Independence for Case-Control Data. <i>American Journal of Epidemiology</i> , 2012, 176, 1060-1067.	3.4	37
237	Alcohol Consumption and Survival after a Breast Cancer Diagnosis: A Literature-Based Meta-analysis and Collaborative Analysis of Data for 29,239 Cases. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 934-945.	2.5	37
238	Urinary bisphenol A-glucuronide and postmenopausal breast cancer in Poland. <i>Cancer Causes and Control</i> , 2014, 25, 1587-1593.	1.8	37
239	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. <i>American Journal of Human Genetics</i> , 2015, 97, 22-34.	6.2	37
240	Estimating breast cancer mortality reduction and overdiagnosis due to screening for different strategies in the United Kingdom. <i>British Journal of Cancer</i> , 2014, 110, 2412-2419.	6.4	36
241	Large-Scale Pathway-Based Analysis of Bladder Cancer Genome-Wide Association Data from Five Studies of European Background. <i>PLoS ONE</i> , 2012, 7, e29396.	2.5	36
242	Coffee consumption, genetic susceptibility and bladder cancer risk. <i>Cancer Causes and Control</i> , 2009, 20, 121-127.	1.8	35
243	Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. <i>Breast Cancer Research</i> , 2012, 14, R152.	5.0	35
244	11q13 is a susceptibility locus for hormone receptor positive breast cancer. <i>Human Mutation</i> , 2012, 33, 1123-1132.	2.5	35
245	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. <i>International Journal of Cancer</i> , 2021, 148, 307-319.	5.1	35
246	Parity-related molecular signatures and breast cancer subtypes by estrogen receptor status. <i>Breast Cancer Research</i> , 2014, 16, R74.	5.0	34
247	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. <i>International Journal of Cancer</i> , 2015, 136, E685-96.	5.1	34
248	Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv223.	6.3	34
249	Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies. <i>Breast Cancer Research</i> , 2019, 21, 62.	5.0	34
250	Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. <i>International Journal of Epidemiology</i> , 2007, 36, 236-241.	1.9	33
251	Folate metabolism genes, vegetable intake and renal cancer risk in central Europe. <i>International Journal of Cancer</i> , 2008, 122, 1710-1715.	5.1	33
252	Missense Variants in <i>ATM</i> in 26,101 Breast Cancer Cases and 29,842 Controls. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2143-2151.	2.5	33

#	ARTICLE	IF	CITATIONS
253	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. <i>Human Molecular Genetics</i> , 2016, 25, 3863-3876.	2.9	33
254	Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study. <i>International Journal of Cancer</i> , 2021, 148, 2712-2723.	5.1	33
255	Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 287-294.	2.5	32
256	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. <i>Human Molecular Genetics</i> , 2014, 23, 1934-1946.	2.9	32
257	Transcriptome-wide association study of breast cancer risk by estrogen receptor status. <i>Genetic Epidemiology</i> , 2020, 44, 442-468.	1.3	32
258	Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1543-6.	2.5	32
259	Commentary: Reflections on G. M. Lower and colleagues'™ 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned. <i>International Journal of Epidemiology</i> , 2007, 36, 23-28.	1.9	31
260	Does increased urination frequency protect against bladder cancer?. <i>International Journal of Cancer</i> , 2008, 123, 1644-1648.	5.1	31
261	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. <i>Oncotarget</i> , 2016, 7, 80140-80163.	1.8	31
262	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016, 18, 64.	5.0	31
263	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. <i>Nature Communications</i> , 2020, 11, 312.	12.8	30
264	Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. <i>British Journal of Cancer</i> , 2010, 103, 1097-1102.	6.4	29
265	Prolactin Receptor Expression and Breast Cancer: Relationships with Tumor Characteristics among Pre- and Post-menopausal Women in a Population-Based Case-Control Study from Poland. <i>Hormones and Cancer</i> , 2014, 5, 42-50.	4.9	29
266	Molecular Pathology in Epidemiologic Studies: A Primer on Key Considerations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 966-972.	2.5	28
267	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. <i>BMC Cancer</i> , 2013, 13, 28.	2.6	28
268	Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions. <i>Genetic Epidemiology</i> , 2014, 38, 84-93.	1.3	28
269	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 38.	5.2	28
270	Reproductive factors and risk of breast cancer by tumor subtypes among Ghanaian women: A population-based case-control study. <i>International Journal of Cancer</i> , 2020, 147, 1535-1547.	5.1	28

#	ARTICLE	IF	CITATIONS
271	Variability of Nasal Lavage Polymorphonuclear Leukocyte Counts in Unexposed Subjects: Its Potential Utility for Epidemiology. Archives of Environmental Health, 1994, 49, 267-272.	0.4	27
272	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptorâ€“Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	2.5	27
273	Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study. Gynecologic Oncology, 2011, 120, 167-173.	1.4	27
274	Association of Active and Sedentary Behaviors with Postmenopausal Estrogen Metabolism. Medicine and Science in Sports and Exercise, 2016, 48, 439-448.	0.4	27
275	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genomeâ€“wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	3.1	26
276	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	5.0	26
277	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26
278	Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes. Environment International, 2020, 135, 105346.	10.0	25
279	No Association between <i>FTO</i> or <i>HHEX</i> and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2106-2109.	2.5	24
280	Differential urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in the urea transporter gene, <i>SLC14A1</i> . International Journal of Cancer, 2013, 133, 3008-3013.	5.1	24
281	The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease. Cancer Research, 2014, 74, 5808-5818.	0.9	24
282	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2015, 1, 18-32.	3.0	24
283	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
284	Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Research, 2019, 21, 144.	5.0	24
285	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. Nature Communications, 2021, 12, 4198.	12.8	24
286	Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women. Pharmacogenetics and Genomics, 2006, 16, 547-553.	1.5	23
287	Absolute Risk Models for Subtypes of Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 1657-1659.	6.3	23
288	Genetic variation in CYP17 and endometrial cancer risk. Human Genetics, 2008, 123, 155-162.	3.8	23

#	ARTICLE	IF	CITATIONS
289	Polymorphism in the <i>GALNT1</i> Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women: The Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 600-604.	2.5	23
290	Active and passive cigarette smoking and the risk of endometrial cancer in Poland. <i>European Journal of Cancer</i> , 2010, 46, 690-696.	2.8	23
291	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. <i>Human Genetics</i> , 2014, 133, 481-497.	3.8	23
292	Measurement of Sex Steroid Hormones in Breast Adipocytes: Methods and Implications. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1891-1895.	2.5	22
293	Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. <i>International Journal of Cancer</i> , 2009, 124, 1716-1720.	5.1	22
294	Comprehensive Assessment of Genetic Variation of Catechol-O-Methyltransferase and Breast Cancer Risk. <i>Cancer Research</i> , 2006, 66, 9781-9785.	0.9	21
295	Common Genetic Variation in GATA-Binding Protein 3 and Differential Susceptibility to Breast Cancer by Estrogen Receptor α Tumor Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 2269-2275.	2.5	21
296	Estrogen receptor and progesterone receptor expression in normal terminal duct lobular units surrounding invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 837-847.	2.5	21
297	Application of Multi-SNP Approaches Bayesian LASSO and AUC-RF to Detect Main Effects of Inflammatory-Gene Variants Associated with Bladder Cancer Risk. <i>PLoS ONE</i> , 2013, 8, e83745.	2.5	21
298	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	3.4	21
299	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. <i>British Journal of Cancer</i> , 2014, 110, 1088-1100.	6.4	21
300	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. <i>Cancer Causes and Control</i> , 2016, 27, 679-693.	1.8	21
301	Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. <i>International Journal of Epidemiology</i> , 2020, 49, 216-232.	1.9	21
302	Intake of fruits, and vegetables in relation to breast cancer risk by hormone receptor status. <i>Breast Cancer Research and Treatment</i> , 2007, 107, 113-117.	2.5	20
303	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	2.5	20
304	SNP-SNP interaction analysis of NF- κ B signaling pathway on breast cancer survival. <i>Oncotarget</i> , 2015, 6, 37979-37994.	1.8	20
305	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. <i>Breast Cancer Research</i> , 2015, 17, 18.	5.0	20
306	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. <i>International Journal of Cancer</i> , 2017, 141, 1830-1840.	5.1	20

#	ARTICLE	IF	CITATIONS
307	Inherited Variants in Regulatory T Cell Genes and Outcome of Ovarian Cancer. PLoS ONE, 2013, 8, e53903.	2.5	20
308	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1793-1797.	2.5	19
309	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 2016, 6, 32512.	3.3	19
310	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. Journal of Pathology: Clinical Research, 2016, 2, 138-153.	3.0	19
311	CWAS meta-analysis of 16 852 women identifies new susceptibility locus for endometrial cancer. Human Molecular Genetics, 2016, 25, ddw092.	2.9	19
312	The <i>BRCA2</i> c.68-7T>A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Human Mutation, 2018, 39, 729-741.	2.5	19
313	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. International Journal of Cancer, 2018, 143, 746-757.	5.1	19
314	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. Breast Cancer Research and Treatment, 2019, 173, 667-677.	2.5	19
315	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
316	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 623-642.	2.5	19
317	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
318	Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case-control study in Poland. Breast Cancer Research, 2011, 13, R42.	5.0	18
319	Genetic Variation in the TP53 Pathway and Bladder Cancer Risk. A Comprehensive Analysis. PLoS ONE, 2014, 9, e89952.	2.5	18
320	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
321	Identification and replication of the interplay of four genetic high-risk variants for urinary bladder cancer. Carcinogenesis, 2017, 38, 1167-1179.	2.8	18
322	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	3.8	18
323	Study of genes and environmental factors in complex diseases. Lancet, The, 2002, 359, 1155.	13.7	17
324	Effects of Electron-Beam Irradiation on Whole Genome Amplification. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1016-1019.	2.5	17

#	ARTICLE	IF	CITATIONS
325	Occupation and breast cancer risk in Polish women: A population-based case-control study. American Journal of Industrial Medicine, 2007, 50, 97-111.	2.1	17
326	Micronuclei assessment in the urothelial cells of women using hair dyes and its modulation by genetic polymorphisms. Cancer Letters, 2008, 263, 259-266.	7.2	17
327	LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk. British Journal of Cancer, 2014, 110, 2123-2130.	6.4	17
328	Intrauterine environment and breast cancer risk in a population-based case-control study in Poland. International Journal of Cancer, 2006, 119, 2136-2141.	5.1	16
329	Breast cancer susceptibility risk associations and heterogeneity by E-cadherin tumor tissue expression. Breast Cancer Research and Treatment, 2014, 143, 181-187.	2.5	16
330	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
331	An investigation of the association of genetic susceptibility risk with somatic mutation burden in breast cancer. British Journal of Cancer, 2016, 115, 752-760.	6.4	16
332	Tracing Lung Cancer Risk Factors Through Mutational Signatures in Never-Smokers. American Journal of Epidemiology, 2021, 190, 962-976.	3.4	16
333	Skewed X chromosome inactivation and early-onset breast cancer. Journal of Medical Genetics, 2005, 43, 48-53.	3.2	15
334	Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma. Diagnostic Molecular Pathology, 2006, 15, 157-161.	2.1	15
335	Plasma Carotenoid- and Retinol-Weighted Multi-SNP Scores and Risk of Breast Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 927-936.	2.5	15
336	Maximizing DNA Yield for Epidemiologic Studies: No More Buffy Coats?. American Journal of Epidemiology, 2013, 178, 1170-1176.	3.4	15
337	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Medicine, 2021, 13, 15.	8.2	15
338	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. Oncotarget, 2015, 6, 7390-7407.	1.8	15
339	Association of COMT haplotypes and breast cancer risk in caucasian women. Anticancer Research, 2010, 30, 217-20.	1.1	15
340	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
341	Quantitation of DNA in buccal cell samples collected in epidemiological studies. Biomarkers, 2006, 11, 472-479.	1.9	14
342	Bulky DNA Adduct Formation and Risk of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2155-2159.	2.5	14

#	ARTICLE	IF	CITATIONS
343	Genome-wide CNV analysis replicates the association between GSTM1 deletion and bladder cancer: a support for using continuous measurement from SNP-array data. BMC Genomics, 2012, 13, 326.	2.8	14
344	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
345	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
346	Invited Commentary: Screening and the Elusive Etiology of Prostate Cancer. American Journal of Epidemiology, 2015, 182, 390-393.	3.4	14
347	Recruiting population controls for case-control studies in sub-Saharan Africa: The Ghana Breast Health Study. PLoS ONE, 2019, 14, e0215347.	2.5	14
348	A response to "Personalised medicine and population health: breast and ovarian cancer". Human Genetics, 2019, 138, 287-289.	3.8	14
349	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. Breast Cancer Research and Treatment, 2020, 181, 423-434.	2.5	14
350	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. Oncotarget, 2017, 8, 18381-18398.	1.8	14
351	Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. Journal of the National Cancer Institute, 2022, 114, 1706-1719.	6.3	14
352	Genetic Variation in the Androgen Receptor Gene and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 585-589.	2.5	13
353	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
354	Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLoS ONE, 2015, 10, e0143256.	2.5	13
355	Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk. International Journal of Cancer, 2020, 146, 2130-2138.	5.1	13
356	Effects of Electron-Beam Irradiation on Buccal-Cell DNA. American Journal of Human Genetics, 2003, 73, 646-651.	6.2	12
357	Measurement of urine pH for epidemiological studies on bladder cancer. European Journal of Epidemiology, 2007, 22, 91-98.	5.7	12
358	CHEK2, MGMT, SULT1E1 and SULT1A1 Polymorphisms and Endometrial Cancer Risk. Twin Research and Human Genetics, 2011, 14, 328-332.	0.6	12
359	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
360	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12

#	ARTICLE	IF	CITATIONS
361	<i>HSD17B1</i> Genetic Variants and Hormone Receptor-Defined Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2766-2772.	2.5	11
362	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. <i>International Journal of Cancer</i> , 2013, 132, 2044-2055.	5.1	11
363	Whole Genome Prediction of Bladder Cancer Risk With the Bayesian LASSO. <i>Genetic Epidemiology</i> , 2014, 38, 467-476.	1.3	11
364	Toward Risk-Stratified Breast Cancer Screening: Considerations for Changes in Screening Guidelines. <i>JAMA Oncology</i> , 2020, 6, 31.	7.1	11
365	A mixed-model approach for powerful testing of genetic associations with cancer risk incorporating tumor characteristics. <i>Biostatistics</i> , 2020, 22, 772-788.	1.5	11
366	Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors. <i>Clinical Cancer Research</i> , 2021, 27, 3725-3733.	7.0	11
367	Polygenic risk scores for prediction of breast cancer risk in women of African ancestry: a cross-ancestry approach. <i>Human Molecular Genetics</i> , 2022, 31, 3133-3143.	2.9	11
368	Association of <i>CYP1B1</i> Haplotypes and Breast Cancer Risk in Caucasian Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1321-1323.	2.5	10
369	Asthma status is associated with decreased risk of aggressive urothelial bladder cancer. <i>International Journal of Cancer</i> , 2018, 142, 470-476.	5.1	10
370	Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer. <i>Cancer Research</i> , 2022, 82, 25-35.	0.9	10
371	Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast. <i>International Journal of Cancer</i> , 2017, 140, 825-832.	5.1	9
372	Assessment of breast cancer risk: which tools to use?. <i>Lancet Oncology</i> , The, 2019, 20, 463-464.	10.7	9
373	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. <i>British Journal of Cancer</i> , 2021, 125, 1135-1145.	6.4	9
374	<i>PHIP</i> - a novel candidate breast cancer susceptibility locus on 6q14.1. <i>Oncotarget</i> , 2017, 8, 102769-102782.	1.8	9
375	Ovarian volumes among women with endometrial carcinoma: Associations with risk factors and serum hormones. <i>Gynecologic Oncology</i> , 2007, 107, 431-435.	1.4	8
376	Searching for Blood DNA Methylation Markers of Breast Cancer Risk and Early Detection. <i>Journal of the National Cancer Institute</i> , 2013, 105, 678-680.	6.3	8
377	Inflammatory-Related Genetic Variants in Non-Muscle-Invasive Bladder Cancer Prognosis: A Multimarker Bayesian Assessment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1144-1150.	2.5	8
378	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. <i>Human Genetics</i> , 2016, 135, 137-154.	3.8	8

#	ARTICLE	IF	CITATIONS
379	Application of Biomarkers in Cancer Epidemiology. , 2006, , 70-88.		8
380	The case for increasing diversity in tissue-based functional genomics datasets to understand human disease susceptibility. Nature Communications, 2022, 13, .	12.8	8
381	Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients. Breast Cancer Research and Treatment, 2015, 150, 457-466.	2.5	7
382	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. British Journal of Cancer, 2016, 114, 298-304.	6.4	7
383	Reply to “Mosaic loss of chromosome Y in leukocytes matters”™. Nature Genetics, 2019, 51, 7-9.	21.4	7
384	Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1397-1407.	2.5	7
385	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
386	Clarifying breast cancer risks associated with menopausal hormone therapy. Lancet Oncology, The, 2006, 7, 885-886.	10.7	6
387	Detectible mosaic truncating PPM1D mutations, age and breast cancer risk. Journal of Human Genetics, 2019, 64, 545-550.	2.3	6
388	Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer. Breast Cancer Research and Treatment, 2021, 189, 483-495.	2.5	6
389	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
390	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
391	Analysis of epidemiologic studies of genetic effects and gene-environment interactions. IARC (international Agency for Research on Cancer) Scientific Publications, 2011, , 281-301.	0.4	6
392	A Genome-Wide Gene-Based Gene-Environment Interaction Study of Breast Cancer in More than 90,000 Women. Cancer Research Communications, 2022, 2, 211-219.	1.7	6
393	Whole genome amplification of buccal cytobrush DNA collected for molecular epidemiology studies. Biomarkers, 2007, 12, 303-312.	1.9	5
394	7q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium. Journal of Medical Genetics, 2011, 48, 698-702.	3.2	5
395	Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study. Carcinogenesis, 2011, 32, 1862-1866.	2.8	5
396	Fine mapping of 14q24.1 breast cancer susceptibility locus. Human Genetics, 2012, 131, 479-490.	3.8	5

#	ARTICLE	IF	CITATIONS
397	Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 341-350.	2.5	5
398	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019, 9, 12524.	3.3	5
399	Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast. <i>Npj Breast Cancer</i> , 2020, 6, 41.	5.2	5
400	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	6.4	5
401	Disinfection By-Products in Drinking Water and Bladder Cancer: Evaluation of Risk Modification by Common Genetic Polymorphisms in Two Caseâ€“Control Studies. <i>Environmental Health Perspectives</i> , 2022, 130, 57006.	6.0	5
402	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. <i>British Journal of Cancer</i> , 2011, 105, 1934-1939.	6.4	4
403	Discovery of structural deletions in breast cancer predisposition genes using whole genome sequencing data fromâ€“>â€“2000 women of African-ancestry. <i>Human Genetics</i> , 2021, 140, 1449-1457.	3.8	4
404	Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa. <i>Npj Precision Oncology</i> , 2021, 5, 83.	5.4	4
405	Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana Breast Health Study. <i>Breast Cancer Research</i> , 2022, 24, 9.	5.0	4
406	Re: More data regarding the effects of passive smoking on breast cancer risk among younger women. <i>International Journal of Cancer</i> , 2007, 120, 2517-2518.	5.1	3
407	Cancer Informatics for Cancer Centers (CI4CC): Building a Community Focused on Sharing Ideas and Best Practices to Improve Cancer Care and Patient Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 108-116.	2.1	3
408	Oncologic Therapy for Solid Tumors Alters the Risk of Clonal Hematopoiesis. <i>Blood</i> , 2018, 132, 747-747.	1.4	3
409	Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients. <i>Human Genetics and Genomics Advances</i> , 2021, 3, 100076.	1.7	3
410	Relation of circulating estrogens with hair relaxer and skin lightener use among postmenopausal women in Ghana. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2023, 33, 301-310.	3.9	3
411	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention. <i>Preventive Medicine</i> , 2022, 159, 107075.	3.4	3
412	Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1593-1601.	2.5	3
413	Peripheral blood immunologic phenotype of populationâ€“based breast cancer cases and matched controls. <i>European Journal of Clinical Investigation</i> , 2012, 42, 572-574.	3.4	2
414	rs2735383, located at a microRNA binding site in the 3â€“UTR of NBS1, is not associated with breast cancer risk. <i>Scientific Reports</i> , 2016, 6, 36874.	3.3	2

#	ARTICLE	IF	CITATIONS
415	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
416	Browser-based Data Annotation, Active Learning, and Real-Time Distribution of Artificial Intelligence Models: From Tumor Tissue Microarrays to COVID-19 Radiology. Journal of Pathology Informatics, 2021, 12, 38.	1.7	2
417	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. The Clinical Journal of Pathology, 2014, , n/a-n/a.	0.0	2
418	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. Scientific Reports, 2021, 11, 19787.	3.3	2
419	TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 124-131.	2.5	2
420	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	3.3	2
421	RE: Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic. Journal of the National Cancer Institute, 2018, 110, 1273-1274.	6.3	1
422	Large-scale evaluation of candidate genes for cancer identifies common genetic variants in vascular endothelial growth factor associated with bladder cancer risk. PLoS Genetics, 2005, preprint, e29.	3.5	1
423	Abstract 2320: Evaluating a polygenic risk score for breast cancer in women of African ancestry. , 2020, , .		1
424	Abstract 4613: Cross-ancestry genome-wide association study identifies six new loci for breast cancer in women of African and european ancestry. , 2020, , .		1
425	Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. Npj Breast Cancer, 2022, 8, .	5.2	1
426	Reply: Study design and statistics in epidemiology of breast cancer. British Journal of Cancer, 2006, 95, 1302-1303.	6.4	0
427	Modifications to a Standard Buccal Collection Protocol: Effects on Human DNA Yield. Cell Preservation Technology, 2007, 5, 216-224.	0.6	0
428	An unusual suspect: an uncommon human-specific synonymous coding variant within the UGT1A6 gene explains a GWAS signal and protects against bladder cancer. Genome Biology, 2011, 12, .	8.8	0
429	A novel functional variant in 8q24 is associated with regulation of prostate stem cell antigen (PSCA) gene expression and bladder cancer risk. Genome Biology, 2011, 12, .	8.8	0
430	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1028-1031.	2.5	0
431	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. Obstetrical and Gynecological Survey, 2015, 70, 758-762.	0.4	0
432	Response. Journal of the National Cancer Institute, 2016, 108, djv441.	6.3	0

#	ARTICLE	IF	CITATIONS
433	Abstract 81: Studying Ghanian Cancer Genomes Using Cell-free DNA. , 2021, , .		0
434	Design Considerations in Molecular Epidemiology. , 2008, , 1-18.		0